Enhanced proliferation of functionally competent bone marrow cells in different strains of mice treated with swainsonine

International Immunopharmacology

Volumn 3, Issue 3, 2003, Pages 445-455

  Oredipe, Oladipo A ^a,b   Furbert Harris, Paulette M ^a,b   Laniyan, Ibrahim ^a,b   Green, William R ^a   White, Sandra L ^c   Olden, Kenneth ^d   Parish Gause, Debra ^b   Vaughn, Theresa ^b   Griffin, Walter M ^b   Sridhar, Rajagopalan ^a,b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Colony forming units granulocyte erythrocyte monocyte megakaryocyte (CFU GEMM or CFU Mix); Colony forming units granulocyte macrophage (CFU GM); Erythroid burst forming units (BFUe); Immunomodulation; Swainsonine

Indexed keywords

SWAINSONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW CELL; BURST FORMING UNIT E; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL LEVEL; CELL LINEAGE; CELL PROLIFERATION; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOCRIT; LEUKOCYTE; LONG TERM EXPOSURE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

EID: 0037333885     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00042-0     Document Type: Article

References (35)

1. Savarese D.M.F., Hsieh C., Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J. Clin. Oncol. 15:1997;2981-2995.
2. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24:1997;S10-3-S10-10.
3. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. J. Am. Med. 69:1980;585-594.
4. Hryniuk W.M., Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4:1986;1162-1170.
5. Crown J. Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer. J. Eur. Cancer. 33(S7):1997;S15-S19.
6. Honkoop A.H., Wagstaff J., Pinedo H.M. Management of stage III breast cancer. Oncology. 55:1998;218-227.
7. Oredipe O.A., White S.L., Grzegorzewski K., Gause B.L., Cha J.K., Miles V.A.et al. Protective effects of swainsonine on murine survival and bone marrow proliferation during cytotoxic chemotherapy. J. Natl. Cancer Inst. 83:1991;1149-1156.
8. Klein J.L., Roberts J.D., George M.D., Kurtzberg J., Breton P., Chermann J.C.et al. Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. J. Br. Cancer. 80:1999;87-95.
9. White S.L., Nagai T., Akiyama S.K., Reeves E.J., Grzegorzewski K., Olden K. Swainsonine stimulation of the proliferation and colony forming activity of murine bone marrow. Cancer Commun. 3:1991;83-91.
10. k) expression, and interleukin-1 production by swainsonine. Cancer Commun. 1:1989;373-379.
11. Bowlin T.L., Sunkara P.S. Swainsonine, an inhibitor of glycoprotein processing, enhances mitogen induced interleukin-2 production and receptor expression in human lymphocytes. Biochem. Biophys. Res. Commun. 151:1988;846-859.
12. Wheldon T.E., Michalowski A.S., Kirk J. The effect of irradiation on function and self renewing normal tissues with differing proliferative organisation. J. Br. Radiol. 55:1982;759-766.
13. Wheldon T.E., Michalowski A.S. Alternative models for the proliferative structure of normal tissues and their response to irradiation. J. Br. Cancer. 53(Suppl. VII):1986;382-385.
14. Oredipe O.A., Furbert-Harris P.M., Green W.R., White S.L., Olden K., Laniyan I.et al. Swainsonine stimulates bone marrow cell proliferation and differentiation in different strains of inbred mice. Pharmacol. Res. 47(1):2003;69-74.
15. Mohla S., White S.L., Grzegorzewski K., Nielsen D., Dunston G., Dickson L.A.et al. Inhibition of growth of subcutaneous xenografts and metastases of human breast carcinoma by swainsonine: modulation of tumor cell HLA class I antigens and host effector mechanisms. Anticancer Res. 10:1990;1515-1522.
16. Humphries M.J., Matsumoto K., White S.L., Molyneux R.J., Olden K. Augmentation of natural killer cell activity by swainsonine, a new antimetastaic immunomodulator. Cancer Res. 48:1988;1410-1415.
17. Das P.C., Roberts J.D., White S.L., Olden K. Activation of resident tissue-specific macrophages by swainsonine. Oncol. Res. 7:1995;425-433.
18. Moore M.A.S., Warren D.J. Synergy of interleukin-1 and granulocyte-colony stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7134-7138.
19. Castelli M.P., Black P.L., Schneider M., Pennington R., Abe F., Talmadge J.E. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J. Immunol. 140:1988;3830-3837.
20. Benjamin W.R., Tare N.S., Hayes T.J., Becker J.M., Anderson T.D. Regulation of hematopoiesis in myelosuppressed mice by human recombinant IL-1α J. Immunol. 142:1989;792-799.
21. White S.L., Griffin W., Oredipe O.A., Olden K. In vitro colony stimulation activity of swainsonine. Proc. Am. Assoc. Cancer Res. 33:1992;520.
22. Rosenfeld C.S., Nemunaitis J. The role of granulocyte-macrophage colony-stimulating factor - stimulated progenitor cells in oncology. Semin. Hematol. 29(Suppl. 3):1992;19-26.
23. Bronchud M.H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T.M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. J. Br. Cancer. 60:1989;121-125.
24. Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 92:1998;4491-4508.
25. Armstrong DK, Davidson NE. Dose intensity for breast cancer. Oncology (Huntingt) 2001;15:701-8, 712-4, 717-8.
26. Dorling P.R., Huxtable C.R., Colegate S.M. Inhibition of lysosomal α-mannosidase (EC 3.2.1.24) by swainsonine, an indolizidine alkaloid isolated from Swainsona canescens. J. Biochem. 191:1980;649-651.
27. Elbein E.D. Inhibitors of biosynthesis of N-linked oligosaccharide chains. Annu. Rev. Biochem. 56:1987;497-534.
28. Van den Elsen J.M., Kuntz D.A., Rose D.R. Structure of Golgi alpha-mannosidase: II. A target for inhibition of growth and metastasis of cancer cells. EMBO J. 20:2001;3008-3017.
29. Granerus M., Engstrom W. The effects of glycosylation inhibitors on the proliferation of a Wilms tumour cell line. Anticancer Res. 20:2000;689-692.
30. Goss P.E., Baptiste J., Fernandes B., Baker M., Dennis J.W. A phase I study of swainsonine in patients with advanced malignancies. Cancer Res. 54:1994;1450-1457.
31. Kino T., Inamura N., Nakahara K., Kiyoto S., Goto T., Terano H.et al. Effect of swainsonine on mouse immunodeficient system and experimental murine tumor. J. Antibiot. (Tokyo). 38:1985;936-940.
32. Demetriou M., Nabi I.R., Coppolino M., Dedhar S., Dennis J.W. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J. Cell Biol. 130:1995;383-392.
33. Kojima N., Saito M., Tsuji S. Role of cell surface O-linked oligosaccharides in adhesion of HL60 cells to fibronectin: regulation of integrin-dependent cell adhesion by O-linked oligosaccharide elongation. Exp. Cell Res. 214:1994;537-542.
34. Olden K., Newton S.A., Nagai T., Yasuda Y., Grzegorzewski K., Breton P.et al. The use of novel antineoplastic agents to inhibit the growth and metastasis of malignant melanoma and other cancers. Pigment Cell Res. (Suppl. 2):1992;219-233.
35. Bowen D., Adir J., White S.L., Bowen C.D., Matsumoto K., Olden K. A preliminary pharmacokinetic evaluation of the antimetastatic immunomodulator swainsonine: clinical and toxic implications. Anticancer Res. 13:1993;841-844.